GRF(1-29) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-24. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
==== Commander of the Order of the British Empire (CBE) ==== Civil Danny Chuan Uong Chiu. For services to Business and to the Community. Justice Jeffrey Shepherd. For services to the Legal Sector, to Business and to the Community.
== Collisional reaction interface (CRI) or mini-Collision/Reaction Cell == The proprietary collisional reaction interface (CRI) used in the Bruker ICP-MS Aurora M90 destroys interfering ions. These ions are removed by injecting a collisional gas (He), or a reactive gas (H2), or a mixture of the two, directly into the plasma as it flows through the skimmer cone and/or the sampler cone. Supplying the reactive/collisional gas into the tip of the skimmer cone induces extra collisions and reactions that destroy polyatomic ions in the passing plasma. Fundamentally CRI is a mini- Collision/Reaction Cell installed in front of the parabolic Ion Mirror optics.
=== SEIR model === For many important infections, there is a significant latency period during which individuals have been infected but are not yet infectious themselves. During this period the individual is in compartment E (for exposed).
== Career and research == To juggle parenting and research, Masur moved to the new Medical School at Mount Sinai as an Instructor (part-time) in the Department of Physiology and Biophysics in 1968. where the chairman also provided her with a full-time research assistant. Masur continued as a research associate at Columbia University completing her post-doctoral training in cytochemistry. In collaboration with Eric Holtzman she hypothesized that organelle membrane insertion and removal from the cell surface was the basis for hormone induced alteration in cell membrane permeability. Interest in cell-matrix interaction led her to the cornea where she studied the roles of the extracellular matrix, cell-cell interactions and soluble factors in the wound healing process using a corneal stroma model. Masur's laboratory was funded for 35 years by the National Institutes of Health to explore the hormonal control of membrane transport as well as the cellular mechanisms of wound healing. Her lab determined that myofibroblasts and fibroblasts in the cornea are not "terminally differentiated".
==== Liquid crystal microcapsules ==== Fabrication of liquid crystals has been a point of intrigue for over 5 decades for their anisotropic properties. Microfluidic devices can be used for the synthesis of confined cholesteric liquid crystals through layering of multiple shell-like layers consisting of varying oil-in-water and water-in-oil emulsions. The construction of encapsulated liquid crystals through microfluidic flow of liquid crystal droplets in an immiscible oil allows for monodispersed emulsion layer thickness and composition previously unseen before the advent of microfluidic techniques. The advent of liquid crystal technology has led to advancements in optical displays used both in research and consumer branded products, but more recent discoveries have opened the door to the combination of photon combination and upconversion as well as optical sensors for biological analytes.
Sources: en.wikipedia.org
=== Vertebrates === Vertebrates were once thought to be unable to perform this cycle because there was no evidence of its two key enzymes, isocitrate lyase and malate synthase. However, some research suggests that this pathway may exist in some, if not all, vertebrates.
The First Strike Ration (FSR) is a compact assault United States military ration. It is designed to be consumed on the move during the first 72 hours of conflict. It was created by the United States Army Soldier Systems Center in Natick, Massachusetts. The U.S. Army said the FSR substantially reduces weight and load and is intended to enhance a consumer's physical performance, mental acuity, and mobility. In July 2025, it was replaced by the Close Combat Assault Ration.
== Redox activity == Most selenoproteins have a redox function analogous to proteins with Cys active sites. Two residues of Sec can be oxidized to form a diselenide bond (-Se-Se-), the selenium analog of the disulfide bridge. Sec can also form a selenenyl sulfide (-Se-S-) bond with Cys. The Se-H bond is more easily broken than the S-H bond, resulting in higher reactivity of the Sec residue compared to Cys. Also contributing to reactivity is the higher nucleophilicity, acidity, and leaving-group ability of selenolate (R-Se-) compared to thiolate (R-S-). The Se-Se bond is also weaker than the S-S bond. The result is that the Sec can easily be oxidized and reduced, without much change of getting stuck in one state. Sec is not more reactive than Cys in every single aspect. Selanyl radicals generated from Sec is less prone to attacking aromatic amino acid residues and protein Cα atoms than the thiyl radicals generated from Cys. This offers redox-active selenoproteins some protection from breaking itself apart compared to their cystine-only relatives.
In January 2022, the U.S. DEA proposed scheduling five additional psychedelic tryptamines, including DiPT, 4-HO-DiPT (4-OH-DiPT), 5-MeO-DET, 5-MeO-MiPT, and 5-MeO-AMT. However, they subsequently withdrew this proposal in July 2022. This followed pushback and opposition from the psychedelic community and medical industry. In December 2023, the U.S. DEA proposed scheduling the DOx psychedelics DOC and DOI. As of late 2025, despite opposition to this proposal as well, these drugs are poised to become controlled substances in the near future.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.